Eledon Pharmaceuticals, Inc.
ELDN
$2.06
-$2.04-49.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 113.49% | 85.28% | 68.95% | 85.04% | 25.34% |
| Total Depreciation and Amortization | -11.17% | -40.78% | -55.35% | -53.62% | -49.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -221.65% | -144.73% | -124.48% | -123.12% | -36.35% |
| Change in Net Operating Assets | 1,475.79% | 266.18% | 277.14% | 272.15% | -138.28% |
| Cash from Operations | -70.27% | -42.37% | -19.59% | 6.17% | -17.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.79% | -114.64% | -55.26% | 76.78% | 17.31% |
| Cash from Investing | -64.79% | -114.64% | -55.26% | 76.78% | 17.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 77.99% | 304.74% | 304.40% | 61.60% | 45.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 77.99% | 304.74% | 304.40% | 61.60% | 45.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -36.16% | 106.96% | 130.77% | 104.96% | 49.49% |